These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30907163)

  • 1. Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
    Smolewski P; Rydygier D
    Expert Opin Investig Drugs; 2019 May; 28(5):421-433. PubMed ID: 30907163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Al-Salama ZT; Garnock-Jones KP; Scott LJ
    Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
    Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
    Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
    Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixazomib - the first oral proteasome inhibitor.
    Xie J; Wan N; Liang Z; Zhang T; Jiang J
    Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of ixazomib for the treatment of multiple myeloma.
    Bonnet A; Moreau P
    Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
    J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
    N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
    Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
    J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
    Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
    Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
    Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
    Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixazomib: First Global Approval.
    Shirley M
    Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral ixazomib maintenance therapy in multiple myeloma.
    Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
    Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
    Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.